8-K: Palatin Technologies Announces Positive Phase 2 Results for Ulcerative Colitis and Obesity Programs

Palatin Technologies reports positive topline results from Phase 2 studies of PL8177 for ulcerative colitis and bremelanotide with tirzepatide for obesity.

Summary

• Palatin Technologies announced positive topline results from a Phase 2 study of oral PL8177 for ulcerative colitis.
• The study showed a 33% clinical remission rate in PL8177-treated patients versus 0% on placebo after eight weeks.
• A statistically significant clinical response was demonstrated in 78% of PL8177-treated patients versus 33% on placebo.
• Symptomatic remission was achieved in 56% of PL8177-treated patients versus 33% on placebo.
• The treatment was well-tolerated with no adverse events reported.
• Palatin is advancing licensing discussions with multiple big pharma companies.
• Palatin also announced that bremelanotide co-administered with tirzepatide met its primary endpoint in a Phase 2 obesity study.
• The co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001).
• 40% of patients in the co-administered group achieved a 5% reduction in their body weight (p<0.05).
• IND applications are planned for Palatin's next-generation MC4R long-acting peptides and oral small molecules in 4Q25, with clinical data expected in 1H26.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results for two different programs, indicating potential for future revenue and growth. The management's comments are optimistic, and the company is moving forward with its development plans.

Positives

• PL8177 showed promising results in treating ulcerative colitis, with high rates of clinical remission and response.
• The ulcerative colitis treatment was well-tolerated with no adverse events.
• Bremelanotide co-administered with tirzepatide demonstrated a statistically significant weight reduction in obesity patients.
• The co-administration of bremelanotide and tirzepatide did not increase safety or tolerability concerns.
• Low dose bremelanotide stopped weight regain seen post tirzepatide treatment.
• Palatin is advancing the development of next-generation MC4R agonists for obesity treatment.

Negatives

• The Phase 2 ulcerative colitis study had a small sample size (12 patients), which was not powered to show statistical significance.
• More than 50% of the lost weight was regained within two weeks after treatment cessation in both the co-administration group and the tirzepatide-only group.

Risks

• Clinical trial results may not be indicative of future performance.
• Regulatory approvals are required for product candidates.
• Palatin's ability to fund development and complete clinical trials is subject to risks.
• Competing products may impact commercial acceptance of Palatin's products.
• Weight regain is a common occurrence following the discontinuation of GLP-1/GIP therapy.

Future Outlook

Palatin plans to submit IND applications for its next-generation MC4R long-acting peptides and oral small molecules in 4Q25, with clinical data expected in 1H26. The company is also exploring these therapies as stand-alone treatments and in combination with GLP-1/GIP for various obesity-related conditions.

Management Comments

• Carl Spana, Ph.D., President and CEO of Palatin, stated that they are thrilled with the positive results in the ulcerative colitis study, especially the meaningful and high rates of achievement for clinical remission and clinical response.
• Carl Spana, Ph.D., President & Chief Executive Officer of Palatin, said that the positive results of the obesity study exceeded expectations and demonstrated that co-administration was additive and synergistic.
• Dr. Spana sees hypothalamic obesity as a game-changing opportunity for Palatin, addressing a massive unmet medical need in a multi-billion-dollar market with no approved treatments.

Industry Context

The ulcerative colitis market has existing treatments, but Palatin's PL8177 offers a novel mechanism of action that could provide a safe and effective alternative to immunosuppressive and steroid therapies. The obesity market is dominated by GLP-1 receptor agonists, but Palatin's MC4R agonists represent a validated pathway and promising therapeutic option for addressing obesity and promoting sustained weight management, especially given the drawbacks of GLP-1 therapies.

Comparison to Industry Standards

• The clinical remission rate of 33% in the PL8177-treated group is a promising result compared to existing treatments for ulcerative colitis, such as anti-TNF agents and integrin receptor antagonists, which typically show remission rates in the range of 20-40% in clinical trials.
• The 4.4% weight reduction observed with the co-administration of bremelanotide and tirzepatide is a notable result, especially considering the low doses used in the study; GLP-1 receptor agonists like semaglutide have demonstrated weight reductions of 15-20% in clinical trials, but often come with tolerability issues.
• Palatin's focus on hypothalamic obesity positions them in a unique space, as there are currently no approved treatments for this condition; Rhythm Pharmaceuticals' setmelanotide is another MC4R agonist approved for rare genetic forms of obesity, indicating the potential of this pathway.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and potential licensing deals.
• Employees may benefit from the company's advancement of its development programs.
• Patients with ulcerative colitis and obesity may benefit from new treatment options.
• Potential partners may benefit from collaborations with Palatin on its product candidates.

Next Steps

• Palatin plans to advance licensing discussions for PL8177 with major pharmaceutical companies.
• The company will present complete results from the obesity study at an upcoming medical conference.
• Palatin will submit IND applications for its next-generation MC4R agonists in 4Q25.
• Clinical data from studies of next-generation MC4R agonists is expected in 1H26.

Key Dates

Keywords

ulcerative colitis, obesity, PL8177, bremelanotide, tirzepatide, MC4R agonist, MC1R agonist, clinical trial, Phase 2, Palatin Technologies, weight loss, melanocortin receptor